AbbVie rises as it beats Wall Street estimates, raises 2025 outlook
AbbVie raised its profit outlook for 2025 after reporting sales and profit that beat Wall Street estimates, driven largely by the success of its newer immunology drugs.
The company reported $13.3 billion in sales, compared to the $12.9 billion analysts polled by FactSet were expecting. It also reported adjusted earnings per share of $2.46, more than the $2.38 analysts were anticipating. AbbVie now expects annual earnings per share of $12.09 to $12.29, up from its previous forecast of $11.99 to $12.19.
The success was driven by better-than-expected sales of Skyrizi and Rinvoq, two newer autoimmune medicines that have made up for the shrinking revenue from its blockbuster drug Humira, which had its patent expire in 2023.
The company’s stock rose more than 4% in premarket trading.